GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

Inicio・Lista de Acciones・Vivesto AB

Vivesto AB

Cerrado

0.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.22

Máximo

0.22

Métricas clave
By Trading Economics
Ingresos	2.3M -7.2M
BPA	-0.013
Empleados	4

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.8M 69M
Apertura anterior	0.22
Cierre anterior	0.22

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 dic 2025, 23:54 UTC

Principales Movimientos del Mercado

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dic 2025, 19:08 UTC

Adquisiciones, fusiones, absorciones

Correction to Alphabet to Buy Intersect Article

22 dic 2025, 17:21 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dic 2025, 16:46 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dic 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dic 2025, 23:42 UTC

Charlas de Mercado

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dic 2025, 22:31 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dic 2025, 22:31 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dic 2025, 22:30 UTC

Ganancias

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 dic 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

22 dic 2025, 21:37 UTC

Adquisiciones, fusiones, absorciones

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dic 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dic 2025, 20:54 UTC

Adquisiciones, fusiones, absorciones

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dic 2025, 20:52 UTC

Adquisiciones, fusiones, absorciones

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dic 2025, 20:09 UTC

Charlas de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dic 2025, 19:56 UTC

Charlas de Mercado

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dic 2025, 19:49 UTC

Adquisiciones, fusiones, absorciones

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dic 2025, 19:23 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dic 2025, 19:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 dic 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

22 dic 2025, 19:02 UTC

Charlas de Mercado

Precious Metals Climb to New Heights -- Market Talk

22 dic 2025, 18:45 UTC

Charlas de Mercado

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dic 2025, 18:30 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dic 2025, 18:23 UTC

Adquisiciones, fusiones, absorciones

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dic 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

22 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

22 dic 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.